AVT80 joins FDA review as Alvotech and Teva target both major Entyvio delivery formats

Alvotech is building a wider United States challenge to Takeda Pharmaceutical Company’s Entyvio franchise after regulators accepted AVT80, its proposed interchangeable subcutaneous vedolizumab biosimilar, for formal review. The latest filing gives Alvotech and commercialization partner Teva Pharmaceutical Industries a potential route into self-administered maintenance treatment for ulcerative colitis and Crohn’s disease, complementing the companies’ separate intravenous AVT16 program already under FDA review. The dual-format strategy could prove commercially important because it positions the partnership to compete across both infusion-center and at-home vedolizumab use rather than entering only one part of the treatment pathway. Alvotech shares closed August 31 at $5.19, up 4.85%, as investors responded to another regulatory milestone in a pipeline that is becoming increasingly important to the company’s recovery strategy.

The United States Food and Drug Administration accepted the Biologics License Application covering AVT80 prefilled syringes and autoinjectors for subcutaneous administration. Alvotech is seeking interchangeable biosimilar status, which could permit pharmacy-level substitution for the reference product where state laws allow. The application is supported by analytical, pharmacokinetic and immunogenicity evidence, including a pivotal three-arm study that met all primary endpoints earlier in 2026.

AVT80 gives Alvotech access to the self-administered side of the vedolizumab market

Entyvio is approved for adults with moderately to severely active ulcerative colitis and Crohn’s disease, two chronic inflammatory bowel diseases that can require long-term biologic treatment. Takeda Pharmaceutical Company has expanded the franchise beyond intravenous administration to include subcutaneous maintenance therapy, allowing eligible patients to continue vedolizumab treatment without returning to an infusion center for every dose.

That evolution matters for biosimilar competitors. A company developing only an intravenous alternative risks competing in a shrinking portion of the treatment experience if physicians and patients increasingly favor self-administered maintenance options. Alvotech’s strategy attempts to avoid that problem by developing AVT16 for intravenous use and AVT80 for subcutaneous administration.

AVT80 is being developed in both prefilled syringe and autoinjector formats. If approved, those presentations could potentially allow Alvotech and Teva Pharmaceutical Industries to participate in pharmacy-distributed maintenance treatment while AVT16 addresses intravenous use. The combination could also make the partnership more attractive to payers looking to negotiate access across an entire biologic franchise rather than separate products.

The FDA accepted AVT16 for review in May 2026, meaning Alvotech now has both major vedolizumab formats progressing through the United States regulatory system. The European Medicines Agency has separately validated a marketing authorization application covering AVT16 and AVT80, extending the strategy across another major pharmaceutical market.

This broader approach differentiates the latest filing from a routine biosimilar application. AVT80 does not simply add another molecule to Alvotech’s pipeline. It potentially completes a matched set of products designed to follow patients from intravenous treatment into subcutaneous maintenance.

Interchangeable status could increase AVT80’s commercial flexibility if the FDA approves the biosimilar

Alvotech submitted AVT80 as a proposed interchangeable biosimilar. Under United States law, an FDA-designated interchangeable biosimilar may be substituted for its reference biologic at the pharmacy without the prescribing healthcare provider having to authorize each individual switch, subject to applicable state requirements.

That designation could be particularly relevant for a subcutaneous product. Unlike infusion-administered biologics, which are typically ordered and administered within healthcare facilities, prefilled syringes and autoinjectors may move through specialty pharmacy channels where formulary positioning and substitution rules can play a larger role in determining market share.

Interchangeability would not guarantee rapid adoption. Biosimilar competition increasingly depends on net pricing, rebates, insurance coverage, pharmacy-benefit decisions, contracting and the willingness of physicians and patients to switch from established reference products. Takeda Pharmaceutical Company also benefits from years of physician familiarity with Entyvio and an existing installed patient base.

Still, interchangeable status could give Teva Pharmaceutical Industries another commercial lever when negotiating with payers and specialty pharmacies. A lower-cost biosimilar capable of fitting into the same delivery formats as the reference product may be easier to incorporate into formularies than an alternative that addresses only the intravenous portion of treatment.

The application is backed by a comprehensive similarity package rather than a conventional efficacy trial in inflammatory bowel disease patients. Alvotech said a randomized, double-blind, single-dose, three-arm pharmacokinetic study comparing AVT80 with reference vedolizumab met all primary endpoints. Regulatory advice also indicated that the study could support clinical similarity for both the AVT80 and AVT16 programs. That creates development efficiency for Alvotech by allowing evidence generated around one underlying vedolizumab biosimilar program to support multiple delivery presentations.

Teva Pharmaceutical Industries gives Alvotech an established United States commercialization partner

Alvotech is responsible for developing and manufacturing AVT80, while Teva Pharmaceutical Industries controls United States commercialization under the companies’ long-standing biosimilar partnership. The division of responsibilities allows Alvotech to concentrate on development and manufacturing while relying on an established pharmaceutical company for market access, contracting and sales execution.

That model has already produced commercial products. The partnership has brought biosimilars including SIMLANDI and SELARSDI into the United States market, giving both companies experience competing against large biologic franchises and navigating payer negotiations.

AVT80 and AVT16 could deepen that relationship by adding inflammatory bowel disease to the portfolio. A combined intravenous and subcutaneous vedolizumab offering may also give Teva Pharmaceutical Industries a more substantial contracting position than a single biosimilar presentation would provide.

For Alvotech, the partnership reduces the need to independently construct a large United States commercial organization. That matters because the company is still balancing pipeline investment, manufacturing requirements and a capital structure carrying significant debt.

The financial model nevertheless depends on regulatory approvals translating into actual product sales. Biosimilar markets can become highly competitive once multiple entrants arrive, and reference-product manufacturers can defend share through pricing, rebates and contracting. The value of the AVT80 opportunity will therefore depend not merely on FDA approval but also on launch timing and the competitive environment when the product becomes commercially available.

AVT80 arrives as Alvotech works to restore revenue growth after manufacturing disruption

The regulatory progress comes against a mixed financial backdrop. Alvotech reported adjusted total revenue of $211.9 million for the first half of 2026, down 30.8% from $306.1 million during the same period of 2025. Product and service revenue declined even more sharply, falling 48.3% to $105.9 million.

Management attributed much of the pressure to manufacturing improvements that affected product availability during the first half. Alvotech said production had returned to planned levels by the end of the second quarter and maintained its expectation for stronger performance during the second half of the year.

Adjusted EBITDA reached $46.9 million compared with $53.7 million a year earlier, while the company maintained full-year adjusted revenue guidance of $650 million to $700 million and adjusted EBITDA guidance of $180 million to $220 million. Achieving those forecasts will require a considerable acceleration from the first-half revenue level.

Alvotech ended June with $142.8 million in cash. Its liquidity position was reinforced by approximately $165 million in gross proceeds from an equity offering and private placement, along with a new $75 million term loan facility. Those financing measures provide additional resources for pipeline development and working capital, although they also highlight the capital intensity of operating a global biosimilar manufacturing platform.

Manufacturing execution remains particularly important. The FDA closed an inspection of Alvotech’s Reykjavik facility with a Voluntary Action Indicated classification after issues at the site had previously contributed to delays affecting United States applications. The company has since resubmitted applications for other biosimilar candidates and expects several regulatory decisions during the fourth quarter of 2026.

That regulatory calendar means AVT80 joins a broader group of potential catalysts rather than standing alone. Successful execution across several applications could materially expand Alvotech’s commercial portfolio, while further manufacturing or regulatory setbacks could again delay the revenue growth embedded in management forecasts.

Alvotech stock gains nearly 5% as investors look toward a broader regulatory pipeline

Alvotech shares closed at $5.19 on August 31, up 4.85% from the previous close of $4.95. The move lifted the company’s market capitalization to approximately $1.85 billion, although the valuation remained about 27% below its level a year earlier.

The positive reaction suggests investors viewed the AVT80 acceptance as another indication that Alvotech’s United States regulatory pipeline is moving forward after manufacturing issues complicated earlier applications. The gain should nevertheless be considered within a volatile longer-term stock performance rather than as evidence that the vedolizumab program has already been commercially de-risked.

The central investment issue is increasingly execution. Alvotech already has a large biosimilar pipeline, commercial partnerships and manufacturing capacity. The question is whether the company can convert those assets into a consistent sequence of United States approvals and launches while improving revenue growth and managing its balance sheet.

AVT80 potentially strengthens that case because it complements AVT16 rather than duplicating it. Approval of both candidates would allow Alvotech and Teva Pharmaceutical Industries to approach vedolizumab as a franchise-level opportunity spanning both intravenous and subcutaneous administration.

The risk is that biosimilar economics become increasingly competitive by the time the products reach the market. Discounts, contracting pressure and multiple competing entrants could limit profitability even if regulatory approval is secured. Alvotech must therefore balance the value of a broad portfolio against the reality that each biosimilar does not automatically translate into high-margin revenue.

Still, the FDA acceptance expands the range of opportunities now under regulatory review. If Alvotech can pair successful manufacturing execution with approvals across its late-stage pipeline, the company could emerge from its recent operational difficulties with a materially broader revenue base. AVT80 represents one part of that recovery strategy, but its ability to complement AVT16 across the entire Entyvio treatment pathway makes it more strategically significant than a standalone formulation.

Key takeaways from Alvotech’s AVT80 FDA review and its broader Entyvio biosimilar strategy

• The FDA has accepted Alvotech’s AVT80 Biologics License Application for formal review.
• AVT80 is being developed as an interchangeable subcutaneous biosimilar to Entyvio in both prefilled syringe and autoinjector formats.
• Alvotech already has AVT16, its proposed interchangeable intravenous Entyvio biosimilar, under FDA review.
• Together, AVT16 and AVT80 could give Alvotech and Teva Pharmaceutical Industries coverage across intravenous and subcutaneous vedolizumab treatment.
• A pivotal pharmacokinetic study supporting AVT80 met all primary endpoints and contributes to the evidence package for both candidates.
• Teva Pharmaceutical Industries will commercialize AVT80 in the United States, while Alvotech remains responsible for development and manufacturing.
• Alvotech’s first-half adjusted revenue fell 30.8% to $211.9 million as manufacturing-related issues affected product availability.
• Management continues to forecast $650 million to $700 million in adjusted 2026 revenue and $180 million to $220 million in adjusted EBITDA.
• Alvotech shares closed August 31 at $5.19, up 4.85%, as investors responded to the latest FDA milestone.
• Future investor sentiment will depend on regulatory approvals, manufacturing execution, launch timing and whether Alvotech can convert its large pipeline into sustained revenue growth.